BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops
Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is based in Manchester, the United Kingdom. The company trades on AIM exchange marketplace. The company headquarter is located in Manchester, United Kingdom. The company was established in the 2021. As of writing, the company status seems to be inactive, which indicates it may not be actively trading on the stock exchanges and may be delisted/merged/suspended/renamed.
| Ticker | BVX |
| Long Name | BiVictriX Therapeutics Plc |
| Short Name | Bivictrix Therapeutics PLC |
| Sector | Healthcare |
| Subsector | Biotechnology |
| Subsector 2 | |
| Currency | GBX |
| ISIN | |